Fast Locator 2011-2012: Celsis Analytical Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Celsis Analytical Services



Celsis Analytical Services specializes in methods validation and testing for industry offering a wide range of services in analytical chemistry and microbiological testing for compendial, non-compendial, and client-specific needs, plus stability testing and storage programs. And we're up-to-date on ICH and the latest changes to the USP as well as the Ph EUR and JP.

Analytical Chemistry:
Our chemistry department can perform more than 90% of the testing requirements defined in the United States Pharmacopeia (USP) and its counterparts around the globe. We continuously invest in the latest instrumentation, including multiple HPLC, GC, IC and LC-MS/MS plus dissolution and AA. Count on us for your full monograph testing, with confidence.

Biological Sciences:
Our microbiology scientists combine decades of microbiological testing experience in facilities that are equipped with the latest instrumentation and equipment including two Class 100 clean rooms, DiversiLab strain typing System, Vitek 60® Microbial Identification Systems, Celsis Rapid Detection systems and particle size analyzers.

Stability Testing and Storage:
Since the establishment of pharmaceutical expiration dating provisions, we have led the way in supplying the appropriate testing and storage conditions to meet regulatory and customer demands for product and package stability. From photostability to Zone IV conditions, we can handle your stability testing and storage needs.


Regions covered:

Global: Asia, North America, Europe, Latin America.


Outsourcing services provided:

Analytical Services

  • Chemistry and stability
  • Bioanalytical testing
  • Biosafety and product characterization
  • Microbiology
  • Particle characterization

Website:

www.celsis.com/labs

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here